pharma · Generalized Pustular Psoriasis · Schizophrenia · VNDA
Vanda Pharmaceuticals Netherlands
Vanda Pharmaceuticals Netherlands B.V.
Vanda Pharmaceuticals Netherlands patent portfolio — 56 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US
- Founded
- 2003
- Employees
- 600
- Programs
- 4
- Drugs
- 9
- Patents
- 56
Vanda Pharmaceuticals Netherlands patents
56 pharmaceutical patents indexed for Vanda Pharmaceuticals Netherlands. 0 expire within 24 months.
Vanda Pharmaceuticals Netherlands has 56 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
-
US 9072742
Method of predicting a predisposition to QT prolongation
granted -
US 9074255
Method of predicting a predisposition to QT prolongation
granted -
US 9074254
Method of predicting a predisposition to QT prolongation
granted -
US 9074256
Method of predicting a predisposition to QT prolongation
granted -
US 9060995
Treatment of circadian rhythm disorders
granted -
US 8999638
Method of treatment based on polymorphisms of the KCNQ1 gene
granted -
US 8652776
Prediction of QT prolongation based on SNP genotype
granted -
US 8586610
Methods for the administration of iloperidone
granted
Frequently asked questions
How many patents does Vanda Pharmaceuticals Netherlands have?
56 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Vanda Pharmaceuticals Netherlands patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.